FI963272A - Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia - Google Patents

Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia Download PDF

Info

Publication number
FI963272A
FI963272A FI963272A FI963272A FI963272A FI 963272 A FI963272 A FI 963272A FI 963272 A FI963272 A FI 963272A FI 963272 A FI963272 A FI 963272A FI 963272 A FI963272 A FI 963272A
Authority
FI
Finland
Prior art keywords
indole derivatives
estrogen
treatment
derivatives useful
diseases
Prior art date
Application number
FI963272A
Other languages
English (en)
Swedish (sv)
Other versions
FI963272A0 (fi
Inventor
Alan Joseph Bitonti
Ian Alexander Mcdonald
Francesco Gerald Salituro
Jeffrey Paul Whitten
Esa Tero Jaervi
Paul Steven Wright
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of FI963272A publication Critical patent/FI963272A/fi
Publication of FI963272A0 publication Critical patent/FI963272A0/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/22Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an aralkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C07D209/281-(4-Chlorobenzoyl)-2-methyl-indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FI963272A 1994-02-22 1996-08-21 Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia FI963272A0 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20005794A 1994-02-22 1994-02-22
US36204694A 1994-12-22 1994-12-22
PCT/US1995/001372 WO1995022524A1 (en) 1994-02-22 1995-01-31 Novel indole derivatives useful to treat estrogen-related neoplasms and disorders

Publications (2)

Publication Number Publication Date
FI963272A true FI963272A (fi) 1996-08-21
FI963272A0 FI963272A0 (fi) 1996-08-21

Family

ID=26895427

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963272A FI963272A0 (fi) 1994-02-22 1996-08-21 Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia

Country Status (17)

Country Link
US (1) US5877202A (fi)
EP (1) EP0746544B1 (fi)
JP (1) JP3536258B2 (fi)
KR (1) KR100362864B1 (fi)
CN (1) CN1141627A (fi)
AT (1) ATE170839T1 (fi)
AU (1) AU680740B2 (fi)
CA (1) CA2183731C (fi)
DE (1) DE69504637T2 (fi)
DK (1) DK0746544T3 (fi)
ES (1) ES2122555T3 (fi)
FI (1) FI963272A0 (fi)
HU (1) HUT76133A (fi)
IL (1) IL112700A0 (fi)
NO (1) NO963483L (fi)
NZ (1) NZ281431A (fi)
WO (1) WO1995022524A1 (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
US6150395A (en) * 1997-05-30 2000-11-21 The Regents Of The University Of California Indole-3-carbinol (I3C) derivatives and methods
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
JP2002515484A (ja) * 1998-05-15 2002-05-28 アメリカン・ホーム・プロダクツ・コーポレイション 2−フェニルインドール化合物およびエストロゲン製剤からなる組成物
US6207700B1 (en) * 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
CN1196708C (zh) * 1999-09-13 2005-04-13 惠氏公司 2-(4-羟基-苯基)-1-[4-(2-氨-1-基-乙氧基)-苄基]-1h-吲哚-5-酚的吡喃葡糖苷轭合物
DE19962300A1 (de) * 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
AU2001234958A1 (en) * 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
US6326501B1 (en) * 2000-04-19 2001-12-04 Hoffmann-La Roche Inc. Methylation of indole compounds using dimethyl carbonate
EP1324985A4 (en) * 2000-10-02 2004-10-06 Merck & Co Inc PRENYL PROTEIN TRANSFERASE INHIBITORS
US20030130199A1 (en) * 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
FR2842526B1 (fr) 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
AU2004226479A1 (en) * 2003-03-27 2004-10-14 Evotec Oai Ophthalmic compositions for treating ocular hypertension
CN101031289A (zh) 2004-04-26 2007-09-05 范德比尔特大学 作为具有降低胃肠毒性的治疗剂的吲哚乙酸和茚乙酸衍生物
WO2007013872A2 (en) * 2004-07-22 2007-02-01 The Board Of Trustees Of The University Of Illinois Sensors employing single-walled carbon nanotubes
RU2448703C2 (ru) * 2005-11-23 2012-04-27 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Онкогенное ras-специфичное цитотоксическое соединение и способы его применения
EP2488025A4 (en) 2009-10-15 2013-04-03 Childrens Medical Center SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
CA2845697C (en) 2010-08-30 2020-05-05 Arzeda Corp. Fermentation route for the production of levulinic acid, levulinate esters, valerolactone, and derivatives thereof
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013102242A1 (en) 2012-01-06 2013-07-11 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
US9182350B2 (en) * 2012-03-05 2015-11-10 Dalian University Of Technology Naphthalene-based two-photon fluorescent probes, preparation method and use thereof
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
US10815247B2 (en) * 2016-12-28 2020-10-27 Promega Corporation Functionalized NANOLUC inhibitors
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH483421A (de) * 1964-12-31 1969-12-31 Merck & Co Inc Verfahren zur Herstellung von 2-Phenyl-indolyl-Säuren
DK0431520T3 (da) * 1989-12-04 1995-04-10 Searle & Co Heterocycliske acylaminodiol-beta-aminosyrederivater
EP0518961A1 (fr) * 1990-03-07 1992-12-23 Aventis Pharma S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
EP0639567A1 (en) * 1992-05-08 1995-02-22 Otsuka Pharmaceutical Factory, Inc. Indole derivative
JPH0835029A (ja) * 1994-07-19 1996-02-06 Toyota Motor Corp 高強度高延性鋳造アルミニウム合金およびその製造方法

Also Published As

Publication number Publication date
CA2183731A1 (en) 1995-08-24
DE69504637D1 (de) 1998-10-15
DE69504637T2 (de) 1999-05-06
EP0746544A1 (en) 1996-12-11
HUT76133A (en) 1997-06-30
NO963483L (no) 1996-10-22
ATE170839T1 (de) 1998-09-15
ES2122555T3 (es) 1998-12-16
CN1141627A (zh) 1997-01-29
NZ281431A (en) 1997-09-22
CA2183731C (en) 2000-03-21
NO963483D0 (no) 1996-08-21
WO1995022524A1 (en) 1995-08-24
DK0746544T3 (da) 1999-06-07
AU1837395A (en) 1995-09-04
JP3536258B2 (ja) 2004-06-07
HU9602299D0 (en) 1996-10-28
EP0746544B1 (en) 1998-09-09
FI963272A0 (fi) 1996-08-21
JPH09509169A (ja) 1997-09-16
IL112700A0 (en) 1995-05-26
US5877202A (en) 1999-03-02
KR100362864B1 (ko) 2003-04-16
AU680740B2 (en) 1997-08-07

Similar Documents

Publication Publication Date Title
FI963272A (fi) Uusi indolijohdannaisia, jotka ovat käyttökelpoisia hoitamaan estrogeeniin liittyviä kasvaimia ja sairauksia
DE69717308D1 (de) Verwendung von cntf (ciliary neurotrophic factor) rezeptoraktivatoren fur behandlung von fettleibigkeit
EA199700044A1 (ru) Эстрогенные агенты
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
AR005987A1 (es) Terapia combinada para la osteoporosis
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
DK155143C (da) Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
BR0206985A (pt) Anticorpos modificados e métodos de uso
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE282413T1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
DE69910830D1 (de) Verbindungen und verfahren zur modulation von estrogen rezeptoren
DE69725879D1 (de) VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN
ATE292468T1 (de) Verwendung von biogenen estrogensulfamaten zur hormonsubstitutionstherapie
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
BR0008076A (pt) 16-hidroxiestratrienos como estrogênios de efeito seletivo
BG105125A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
ATE251911T1 (de) Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten
NO994903L (no) Behandling eller profylakse av prostatakreft og benign prostatahyperplasi med selektive östrogenreseptormodulatorer
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
NO980375L (no) Humant MP52 Arg protein
RU2000126276A (ru) Лекарственный препарат для профилактики и/или лечения рака молочной железы, содержащий стероидный ингибитор ароматазы
Shah et al. Bridging technique and science: A review of the molecular signals from long bone development that guiding bone regeneration
ATE168697T1 (de) Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen